BioWorld

May 12, 2009

View Archived Issues

NovImmune Raises $56.5M to Broaden Antibody Pipeline

NovImmune SA secured CHF62.5 million (US$56.5 million) in what may well turn out to be the largest private equity deal completed by a European biotechnology firm this year. (BioWorld Today) Read More

Biotech's Birthplace Fights to Preserve Innovation, Education

Read More

New Target For Inflammatory Aspects of Heart Disease

Read More

Health Groups Form Pact to Cut Costs by $2 Trillion

Read More

Ardea Restructures to Focus on its Clinical Programs

Read More

After Stock Bump, Hemispherx Bringing in $18.3M Publicly

Read More

Roche Partners with Tekmira to Advance Two RNAi Products

Read More

Other News To Note

Read More

Clinic Roundup

Read More